As of 2025-07-20, the Intrinsic Value of Daito Pharmaceutical Co Ltd (4577.T) is 1,155.17 JPY. This 4577.T valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,150.00 JPY, the upside of Daito Pharmaceutical Co Ltd is 0.40%.
The range of the Intrinsic Value is 825.63 - 1,766.05 JPY
Based on its market price of 1,150.00 JPY and our intrinsic valuation, Daito Pharmaceutical Co Ltd (4577.T) is undervalued by 0.40%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 825.63 - 1,766.05 | 1,155.17 | 0.4% |
| DCF (Growth 10y) | 1,514.57 - 3,017.58 | 2,042.64 | 77.6% |
| DCF (EBITDA 5y) | 1,868.77 - 2,236.67 | 2,046.37 | 77.9% |
| DCF (EBITDA 10y) | 2,169.15 - 2,773.38 | 2,453.72 | 113.4% |
| Fair Value | 317.11 - 317.11 | 317.11 | -72.43% |
| P/E | 970.36 - 1,532.87 | 1,141.39 | -0.7% |
| EV/EBITDA | 1,015.52 - 1,633.58 | 1,165.98 | 1.4% |
| EPV | (76.75) - 17.76 | (29.50) | -102.6% |
| DDM - Stable | 620.08 - 1,468.50 | 1,044.29 | -9.2% |
| DDM - Multi | 1,898.94 - 3,493.74 | 2,460.23 | 113.9% |
| Market Cap (mil) | 34,615.00 |
| Beta | 0.31 |
| Outstanding shares (mil) | 30.10 |
| Enterprise Value (mil) | 44,293.00 |
| Market risk premium | 6.13% |
| Cost of Equity | 6.52% |
| Cost of Debt | 4.25% |
| WACC | 5.81% |